Parkinson disease with old-age onset: A comparative study with subjects with middle-age onset

Archives of Neurology

Volumn 60, Issue 4, 2003, Pages 529-533

  Diederich, Nico J ^a,b   Moore, Charity G ^b,c   Leurgans, Sue E ^b   Chmura, Teresa A ^b   Goetz, Christopher G ^b  

^a CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGING; ARTICLE; BRADYKINESIA; CLINICAL EXAMINATION; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RIGIDITY; TREMOR;

ADULT; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; COMORBIDITY; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; LEVODOPA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0037388651     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.4.529     Document Type: Article

References (28)

1. Kubis N, Faucheux BA, Ransmayr G, et al. Preservation of midbrain catechol-aminergic neurons in very old human subjects. Brain. 2000;123:366-373.
2. Koller W, O'Hara R, Weiner W, et al. Relationship of aging to Parkinson's disease. Adv Neurol. 1986;45:317-321.
3. Teravainen H, Forgach L, Hietanen M, Schulzer M, Schoenberg B, Calne DB. The age of onset of Parkinson's disease: etiological implications. Can J Neurol Sci. 1986;13:317-319.
4. Tanner CM. Parkinson's disease. In: Gorelick PB, Alter M, eds. Handbook of Neuroepidemiology. New York, NY: Marcel Dekker Inc; 1994:253-280.
5. Aevarsson O, Svanborg A, Skoog I. Seven-year survival rate after age 85 years: relation to Alzheimer's disease and vascular dementia. Arch Neurol. 1998;55:1226-1232.
6. Critchley M. The neurology of old age. Lancet. 1931;1:1221-1230.
7. Agid Y, Blin J, Bonnet AM, et al. Does aging contribute to aggravation of Parkinson's disease? In: Calne DB, Comi G, Crippa D, Horowski E, Trabucchi M, eds. Parkinsonism and Aging. New York, NY: Raven Press; 1989:115-123.
8. Blin J, Dubois B, Bonnet AM, Vidailhet M, Brandabur M, Agid Y. Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry. 1991;54:780-782.
9. Wolters EC, Calne DB. Is Parkinson's disease related to aging? In: Calne DB, Comi G, Crippa D, Horowski E, Trabucchi M, eds. Parkinsonism and Aging. New York, NY: Raven Press; 1989:125-132.
10. Gibb WRG, Lees A. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology. 1988;38:1402-1406
11. Levy G, Tang MX, Cote LJ, et al. Motor impairment in Parkinson's disease: relationship to incident dementia and age. Neurology. 2000;55:539-544.
12. Hughes AJ, Daniel SE, Balnkson S, Lees AJ. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-148.
13. Petit H, Vermersch P, Pasquier F. Some clinical aspects of late-onset parkinsonism. Clin Neurol Neurosurg. 1992;94(suppl I):S137-S138.
14. Arevalo GG, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord. 1997;12:277-284.
15. Pantelatos A, Fornardi F. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. Adv Neurol. 1993;60:690-697.
16. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology. 1989;39:1187-1190
17. Friedman A. Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand. 1994;89:258-261.
18. Mitchell SL, Sullivan EA, Lipsitz LA. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol. 1997;54:1393-1398.
19. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in the very elderly patients with Parkinson's disease. Mov Disord. 2000;15:664-668.
20. Fahn S, Elton R, and members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden D, Calne B, Goldstein M, eds. Recent Developments in Parkinson Disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-163.
21. Stokes ME, Davis CS, Koch GG. Categorial Data Analysis Using the SAS System. Cary, NC: SAS Institute Inc; 1995:499.
22. Brown H, Prescott R. Applied Mixed Models in Medicine. West Sussex, England: John Wiley & Sons Ltd; 1999.
23. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 1: The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
24. Wong DF, Wagner HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 1984;226:1393-1396.
25. Gorell JM, Johnson CC, Rybiccki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44:1865-1868.
26. Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord. 2001;16:197-201.
27. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol. 1999;56:334-337.
28. Benson RR, Guttmann CRG, Wei X, et al. Older people with impaired mobility have specific loci of periventricular abnormality on MRI. Neurology. 2002;58:48-55.